[HTML][HTML] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
B Asselain, W Barlow, J Bartlett, J Bergh… - The Lancet …, 2018 - thelancet.com
Background Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-
conserving surgery more feasible and might be more likely to eradicate micrometastatic …
conserving surgery more feasible and might be more likely to eradicate micrometastatic …
[HTML][HTML] Advances in the prevention and treatment of obesity-driven effects in breast cancers
K Chen, J Zhang, NM Beeraka, C Tang… - Frontiers in …, 2022 - frontiersin.org
Obesity and associated chronic inflammation were shown to facilitate breast cancer (BC)
growth and metastasis. Leptin, adiponectin, estrogen, and several pro-inflammatory …
growth and metastasis. Leptin, adiponectin, estrogen, and several pro-inflammatory …
Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
LA Korde, MR Somerfield, LA Carey… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere) …
L Gianni, T Pienkowski, YH Im, LM Tseng… - The lancet …, 2016 - thelancet.com
Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant
pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological …
pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological …
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino… - The Lancet, 2014 - thelancet.com
Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …
[HTML][HTML] Systemic therapy for early-stage breast cancer: learning from the past to build the future
E Agostinetto, J Gligorov, M Piccart - Nature Reviews Clinical Oncology, 2022 - nature.com
The treatment of breast cancer has improved dramatically over the past century, from a
strictly surgical approach to a coordinated one, including local and systemic therapies …
strictly surgical approach to a coordinated one, including local and systemic therapies …
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate …
MD Hellmann, JE Chaft, WN William, V Rusch… - The lancet …, 2014 - thelancet.com
Improvements in outcomes for patients with resectable lung cancers have plateaued.
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 …
EP Mamounas, SJ Anderson, JJ Dignam… - Journal of clinical …, 2012 - ascopubs.org
Purpose The limited information on predictors of locoregional recurrence (LRR) after
neoadjuvant chemotherapy (NC) has resulted in controversy about the optimal use of …
neoadjuvant chemotherapy (NC) has resulted in controversy about the optimal use of …
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group
F Sardanelli, C Boetes, B Borisch, T Decker… - European journal of …, 2010 - Elsevier
The use of breast magnetic resonance imaging (MRI) is rapidly increasing. EUSOMA
organised a workshop in Milan on 20–21st October 2008 to evaluate the evidence currently …
organised a workshop in Milan on 20–21st October 2008 to evaluate the evidence currently …
Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial
S Johnston, S Puhalla, D Wheatley, A Ring… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic
breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized …
breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized …